Amgen and the FDA want two different outcomes for Tavneos. What will patients do?

June 12, 2026 01:57 PM EDT PharmaFDA+ Am­gen and the FDA want two dif­fer­ent out­comes for Tavneos. What will pa­tients do? Karen Weintraub Am­gen has asked the FDA to re­view ev­i­dence that its drug Tavneos (ava­co­pan), which treats a rare form of vas­culi­tis, is worth keep­ing on the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER